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Abstract
Background: HTLV-1 is associated with increased susceptibility to Mycobacterium tuberculosis infection and severity
of tuberculosis. Although previous studies have shown that HTLV-1 infected individuals have a low frequency of
positive tuberculin skin test (TST) and decreasing in lymphoproliferative responses compared to HTLV-1 uninfected
persons, these studies were not performed in individuals with history of tuberculosis or evidence of M. tuberculosis
infection. Therefore the reasons why HTLV-1 infection increases susceptibility to infection and severity of
tuberculosis are not understood.The aim of this study was to evaluate how HTLV-1 may influence the clinical,
bacteriologic and immunologic presentation of tuberculosis.
Methods: The study prospectively enrolled and followed 13 new cases of tuberculosis associated with HTLV-1
(cases) and 25 patients with tuberculosis without HTLV-1 infection (controls). Clinical findings, bacterial load in the
sputum, x-rays, immunological response and death were compared in the two groups.
Results: There were no differences in the demographic, clinical and TST response between the two study groups.
IFN-γ and TNF-α production was higher in unstimulated cultures of mononuclear cells of case than in control
patients (p < 0.01). While there was no difference in IFN-γ production in PPD stimulated cultures, TNF-α levels were
lower in cases than in controls (p = 0.01). There was no difference in the bacterial load among the groups but
sputum smear microscopy results became negative faster in cases than in controls. Death only occurred in two
co-infected patients.
Conclusion: While the increased susceptibility for tuberculosis infection in HTLV-1 infected subjects may be related
to impairment in TNF-α production, the severity of tuberculosis in co-infected patients may be due to the
enhancement of the Th1 inflammatory response, rather than in their decreased ability to control bacterial growth.
Keywords: HTLV-1, Tuberculosis, Mycobacterium tuberculosis
Background
The human T cell lymphotropic virus type 1 (HTLV-1)
has a worldwide distribution; it is most prevalent in
Central and South America, Central Africa and south-
western Japan [1]. HTLV-1 infects predominantly CD4 T
cells inducing cell activation and proliferation of both
CD4 and CD8 T cells [2,3]. Moreover, the high produc-
tion of pro-inflammatory cytokines (TNF-α and IFN-γ)
has been associated with central nervous system (CNS)
damage and the development of HTLV-1 associated
myelopathy (HAM) [2,3].
There is evidence that HTLV-1 infection increases se-
verity and susceptibility to strongyloidiasis, scabies and
tuberculosis [4-9]. In patients co-infected with HTLV-1
and Strongyloides stercoralis the exaggerated Th1 im-
mune response and increased regulatory T cell response
decrease the Th2 immune response, which plays a piv-
otal role in host defense against helminthes [9-12].
HTLV-1 infected individuals have two to four-fold
increased chance to acquire tuberculosis [6,13-15]. Add-
itionally, in one retrospective study, it was observed that
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HTLV-1 increased the mortality rate of tuberculosis [8].
Since the frequency of responders to tuberculin skin test
(TST) [16-18] and in vitro lymphocyte proliferation sti-
mulated by protein purified derivate (PPD) is lower
among HTLV-1 infected individuals with tuberculosis
than in HTLV-1 uninfected persons [19], it has been
proposed that a decrease in type 1 immune response to
mycobacterial antigen may increase tuberculosis suscep-
tibility and severity. In this study the clinical, radiologic,
immunologic, and bacteriologic features of patients with
tuberculosis and HTLV-1 infection were compared with
those who had only tuberculosis infection.
Results
There was no significant difference in the demographic
characteristics (age, gender, ethnicity, monthly income
and nutritional status) between the 13 patients with tuber-
culosis and HTLV-1 infection and 25 patients with only
tuberculosis. A large proportion of case (54%) and control
patients (64%) were underweight (body mass index< 18.4)
and the use of alcohol was also similar in both groups.
The clinical manifestations, response to TST and the pres-
ence and quantification of acid-fast bacilli (AFB) in the
sputum in the two groups are shown on Table 1. The
presence of fever, asthenia, anorexia and weight loss
were similar in the two groups (p> 0.05). In both groups
the frequency of hospitalization for tuberculosis,
previous tuberculosis and treatment abandonment for
tuberculosis was high. There was no difference regarding
the frequency of responders to the TST as well as the
size of induration. At the time of admission, two patients
with HTLV-1 infection and tuberculosis had been receiv-
ing therapy for tuberculosis for 28 and 35 days, respect-
ively; in both, the sputum test was negative. However,
previous to the therapy, both were documented to have
AFB in the sputum, which also grew M. tuberculosis in
culture. They were admitted because of toxicity to anti-
tuberculosis drugs. No difference in the bacillary load
was observed in the two groups at admission. The drug
sensibility test revealed one M. tuberculosis isolate with
multidrug resistance and another with resistance to
isoniazid and streptomycin among the cases. In the con-
trol group, there was one isolate with resistance to isonia-
zid, rifampicin and ethambutol and one with resistance to
streptomycin. The findings of the chest x-rays were similar
in the 2 groups. Cavitation was observed in more than
60% of the patients with or without HTLV-1 infection.
Fibrosis and atelectasis occurred in about 50% of the
cases and controls. Parenchymal destruction was higher
(15.3%) in patients with HTLV-1 infection and tubercu-
losis than in patients with only tuberculosis. The
radiologic findings in patients with HTLV-1 and
tuberculosis were not compatible with those observed in
patients with T cell impairment. The most common
Table 1 Clinical and microbiologic characteristics of tuberculosis patients with or without HTLV-1 infection
Characteristic TB with HTLV-1 TB without HTLV-1 p-value
(n = 13) (n = 25)
n (%) n (%)
Symptoms
Fever 11 (84.6) 21 (84.0) 0.67
Asthenia 13 (100) 25 (100) -
Anorexia 11 (84.6) 21 (84.0) 0.35
Weight loss 11 (100) 22 (95.7) -
Prior hospitalization for TB 6 (46.2) 7 (28.0) 0.26
Prior treatment for TB 7 (53.8) 12 (48.0) 0.21
History of treatment abandonment 6 (46.2) 7 (28.0) 0.45
Clinical examinations
Helminth infections 2 (15.4) 3 (12) 0.63
PPD positive 10 (76.9) 14 (63.6) 0.71
Mean PPD (mm) among PPD positive tests, ± SD 12.9 ± 4.0 10.5 ± 4.8 0.23
Sputum bacillary load
0 2 (15.4)* 0 (0)
1+ 5 (38.4) 11 (44.0)
2+ 2 (15.4) 3 (12.0)
3+ 4 (30.8) 11 (44.0)
TB = tuberculosis; HTLV-1 = human lymphotropic virus type 1; SD= standard deviation.
The two patients had already been treated for tuberculosis for one month previous to the admission. Before therapy the smear microscopy result was positive.
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findings were fibrosis, atelectasis, pleural thickening and
cavitation. All of them were similar in the two groups but
the parenchymal destruction lesions were 3.5 fold higher
in patients with HTLV-1 infection and tuberculosis than
in patients only with tuberculosis.
The therapy for tuberculosis was similar in both
groups. The majority of the patients received rifampicin,
isoniazid and pyrazinamide. In 33.3% of the cases and in
28% of the controls, patients also received ethambutol.
Alternative drugs were given to 15.4% of the cases and
to 8% of controls.
Figure 1 shows the survival analysis of patients whose
sputum test became negative after 10 and 20 days of
therapy. As previously stated, two patients with HTLV-1
infection and tuberculosis were already on therapy and
the sputum test was negative. On day 10, while 50%
of the patients with tuberculosis and HTLV-1 still had
AFB in the sputum, almost 90% of patients with tuber-
culosis only remained eliminating bacilli. At day 20,
36.4% of the patients with HTLV-1 infection and tuber-
culosis and 75% of those with tuberculosis only were
smear test positive for AFB (p = 0.07; Kaplan-Meier test).
However, sputum test conversion occurred faster in
patients with HTLV-1 infection and tuberculosis.
The main side effects observed were hepatotoxicity
and gastric intolerance (nausea, abdominal pain and
vomit) observed in, respectively, 38.5% and 23.1% in the
cases and in 28% and 36% in the controls (p > 0.05).
While death was observed in 2 (15.4%) of the patients
with HTLV-1 infection and tuberculosis, none of the
patients died in the group only with tuberculosis. Death
occurred in one woman and one man. They both had
cavitary lung disease, fibrosis, atelectasis and tissue
destruction on chest x-rays. Death was due to acute re-
spiratory insufficiency in one case and sepsis in the
other.
Regarding HTLV-1 infection, the majority of the cases
were HTLV-1 carriers. Four patients had overactive
bladder that is considered to be an oligosymptomatic
form of HAM. The proviral load was quite variable ran-
ging from 8079 to 499742 copies/106cells.
The spontaneous and PPD induced TNF-α and INF-γ
production in supernatants of PBMC are shown in Fig-
ure 2. In cultures without stimulus, the median TNF-α
level among the group with HTLV-1 infection and tuber-
culosis (368 pg/mL) ranging from 128 to 5527 pg/mL
was higher (p = 0.004) than that observed in patients
with only tuberculosis (73 pg/mL), which ranged from 0
to 738 pg/mL (Figure 2A). In cultures stimulated with
PPD, the median and range of TNF-α level in the co-
infected patients, 0 pg/mL (0 – 2295 pg/mL), was lower
(p < 0.01) than in patients with only tuberculosis, which
was 386 pg/mL (0 – 3847 pg/mL) (Figure 2B). The pro-
duction of IFN-γ in unstimulated cultures in patients
with HTLV-1 infection and tuberculosis 732 pg/mL (0 –
2677 pg/mL) was higher (p = 0.004) than in patients with
only tuberculosis, which was 15 pg/mL (0 – 444 pg/mL)
(Figure 2C). There was no difference between the groups
in the production of IFN-γ in PPD stimulated cultures
(Figure 2D). There was no difference (p > 0.05) in the
production of IL-10 in both unstimulated and PPD sti-
mulated cultures; majority of the co-infected patients
(60%) and 45% of patients with tuberculosis without
HTLV-1 infection had no detectable IL-10 production
(data not shown). Addition of anti-IL-10 monoclonal
antibody also did not enhance IFN-γ production
(p > 0.05) in either group (data not shown).
The expression of mRNA for IL-12 in unstimulated
cultures and the production of IFN-γ in PBMC cultures
stimulated with PPD and in cultures with PPD plus ex-
ogenous addition of IL-12 are shown in Figure 3. The
expression of mRNA for IL-12 in unstimulated cultures
was lower in tuberculosis patients with or without co-
infection with HTLV-1 than in seronegative controls
(Figure 3A). Exogenous addition of IL-12 in cultures sti-
mulated with PPD enhanced IFN-γ production similarly
in both groups (Figures 3, B and C).
Discussion
The association between HTLV-1 infection and tubercu-
losis is widely documented, but little is known about the
influence of HTLV-1 on the outcome of M. tuberculosis
infection [6,13-15]. In the present study, the two cases of
death occurred among co-infected patients, but no im-
pairment in the T cell response to PPD was observed
in vivo and in vitro. However, while there was decrease
in TNF-α production in PPD stimulated cultures, the
Figure 1 Survival analysis of sputum smear conversion for acid-
fast bacilli during tuberculosis treatment. Tuberculosis patients
with and without HTLV-1 infection, who remained test positive by
acid-fast bacilli (AFB) smear microscopy after 10 and 20 days of
tuberculosis treatment were evaluated with Kaplan-Meier survival
estimates.
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INF-γ production in unstimulated cultures was higher in
co-infected patients than in patient only with tubercu-
losis. These data together with the observation that the
sputum smear conversion was faster in the cases com-
pared to controls, suggests that impairment in innate
immune response may contribute to acquisition of tu-
berculosis, and that severity of the disease may be due to
exaggerated inflammatory response observed in co-
infected patients.
One important limitation of the present study was the
characteristics of patients with tuberculosis. The admis-
sion for tuberculosis patients is usually due to severity of
disease, severe adverse reactions to anti-tuberculosis
drugs, history of treatment abandonment and documen-
tation of multidrug-resistant M. tuberculosis [20]. In our
case, in addition to the presence of one or more of these
factors, a large percentage of the patients were under-
weight and malnourished, which may have also influ-
enced the clinical course of tuberculosis. Therefore, a
similar type of the study should be performed in out-
patients with less severe tuberculosis manifestations to
determine if the viral infection may change the symp-
toms and x-rays findings of tuberculosis. Nevertheless,
since the frequency of these factors was similar in
tuberculosis patients co-infected or not with HTLV-1,
this study gives support to the previous observation that
HTLV-1 infection worsens the course of tuberculosis [8].
While there is good evidence that HTLV-1 infection
increases the risk for tuberculosis [6,13-15], very little is
known about the clinical course of tuberculosis in such
patients. In a retrospective study, it was shown that
death was significantly more frequent in patients with
tuberculosis and HTLV-1 infection than in patients who
had only tuberculosis [8,14]. However no information
regarding microbiological, radiological or clinical data
were provided to determine how HTLV-1 can exacerbate
the clinical course of tuberculosis. As previous studies
have shown that subjects infected with HTLV-1 have a
decreased immune response “in vivo” and “in vitro” to
PPD [17-19,21], one possibility is that HTLV-1, by de-
creasing the immune response to M. tuberculosis, not
only increases susceptibility but also makes tuberculosis
more severe. The results presented here did not show
any difference in the frequency of patients who respond
to the TST as well as in the size of the induration when
the two groups were compared. These data differ from
the literature, but the population studied here was quite
different from those included in previous studies. In the
Figure 2 TNF-α and IFN-γ production with or without stimulus with PPD. TNF-α and IFN-γ production was determined by ELISA in
supernatants of PBMC culture from co-infected patients and patients with tuberculosis only unstimulated (A and C) or stimulated with PPD (B
and D). Results of PPD stimulated cultures represent values subtracted from the IFN-γ production in unstimulated cultures.
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other studies, data were generated from HTLV-1
infected subjects without documented active tubercu-
losis or even without history of tuberculosis or vaccin-
ation with BCG [16-18]. Here all patients had active
tuberculosis as documented microbiologically.
In vitro studies showed decrease in lymphocyte prolif-
eration and secretion of cytokines upon stimulation with
M. tuberculosis antigen in HTLV-1 infected subjects
compared to controls [19,21]. Similar to the in vivo
observations, the in vitro studies were also performed in
HTLV-1 infected patients without history of tubercu-
losis. However, it is known that abnormalities in T cell
or in antigen present cell function occur in HTLV-1 in-
fection [21-23]. Therefore impairment in the Th1 type of
immune response to mycobacterial antigens may in-
crease susceptibility to tuberculosis. However, our clin-
ical radiologic, microbiologic and immunologic data did
not show any evidence of impairment in the T cell im-
mune response to mycobacterial antigens in patients
with tuberculosis and HTLV-1 infection. For instance
patients with HIV infection have impairment in granu-
loma formation, atypical chest x-ray findings, and slower
time to bacterial conversion [24]. Here all patients had
AFB in the sputum. The majority had cavitation and fi-
brosis on chest x-ray, and parenchymal destruction was
more frequent in patients with tuberculosis and HTLV-1
infection. These are findings observed in immunocom-
petent patients with tuberculosis. Moreover, there was
no difference in the frequency and size of the TST and
there was no difference in IFN-γ production in the two
groups in PPD stimulated cultures. Others have found
increase in bacillary load in patients with HTLV-1 infec-
tion and tuberculosis [14]. In this study we did not find
any difference in the bacillary load, and the sputum test
became negative faster in patients with tuberculosis co-
infected with HTLV-1. Thus, the exaggerated inflamma-
tion with HTLV-1 infection may have contributed to
the rapid sputum smear conversion and to the severity
of tuberculosis. For instance mice lacking IL-27 recep-
tors and mice infected with a M. tuberculosis mce1
operon mutant cannot modulate immune response and
mount an exaggerated inflammatory response asso-
ciated with control of bacterial multiplication, but sur-
vival is decreased due to severe damage of the lung
[25,26].
Compared to seronegative controls, expression of IL-
12 was lower in both groups and exogenous addition of
IL-12 enhanced IFN-γ production in a similar way in tu-
berculosis patients co-infected with HTLV-1 and in
patients with tuberculosis. However, while there was no
difference in IFN-γ production among the groups, in
PPD stimulated cultures, TNF-α was lower in PPD sti-
mulated cultures of patients co-infected with M. tuber-
culosis and HTLV-1. TNF-α plays a key role in
protection against M. tuberculosis [27,28]. Actually em-
phasis has been given for the important role of innate
immune response in the control of M. tuberculosis infec-
tion [29,30]. In such a case, the increased susceptibility
of HTLV-1 infected individuals to M. tuberculosis may
be due to impairment in TNF-α synthesis after exposure
to M. tuberculosis, as well as in other component of the
immune response not yet determined. However, as IFN-
γ production is produced in high levels in HTLV-1 infec-
tion and a type 1 immune response to M. tuberculosis
antigens is not suppressed, granuloma formation is
observed and bacterial growth is controlled. Addition-
ally, as HTLV-1 infection is associated with an exagger-
ated inflammatory response, there is more tissue
Figure 3 Expression of mRNA for IL-12 and IFN-γ production
after exogenous addition of PPD plus IL-12. mRNA for IL-12 was
determined by RT-PCR in unstimulated cultures of PBMC from
seronegative healthy subjects, co-infected patients, and patients
with tuberculosis only (A). IFN-γ production was evaluated by ELISA
in supernatants of PBMC cultures unstimulated or stimulated with
PPD and PPD plus IL-12 in the concentration of 50 μg/ml (B and C).
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damage, which causes severer tuberculosis in HTLV-1
infected subjects.
Conclusions
While the increased susceptibility of HTLV-1 infected
patients to acquire tuberculosis may be due to impaired
TNF-α production, the severity of tuberculosis in
HTLV-1 infected individuals may be related to an
increased inflammatory response.
Methods
The study participants included 13 patients with diagno-
sis of tuberculosis and HTLV-1 infection and 25 patients
who had tuberculosis without HTLV-1. All patients with
tuberculosis consecutively admitted to Hospital Especia-
lizado Octávio Mangabeira (HEOM), Salvador, Brazil,
from August 2007 to July 2009 were tested for HTLV-1
by ELISA and those who tested positive underwent con-
firmation by a Western blot test. The inclusion criteria
were age between 18 to 60 years, diagnosis of tubercu-
losis with documentation of acid-fast bacilli (AFB) by
microscopy in the sputum and serologic test for HTLV-
1. Exclusion criteria included pregnant women, patients
with diabetes, kidney failure, HIV infection and use of
immunosuppressive drugs. For each patient with tuber-
culosis and HTLV-1 infection, two controls with only tu-
berculosis matched by gender and age plus or minus five
years of age were included. A case was defined as a pa-
tient with two sputum tests positive for AFB by micros-
copy and a positive ELISA test for HTLV-1 confirmed
by Western blot. A standardized questionnaire soliciting
demographic and clinical information was completed
for each participant at the time of enrolment into the
study. A pulmonary specialist (MLB) examined each pa-
tient and reviewed laboratory test and the x-ray results.
The patients were evaluated at entrance into the study,
and at 10, 20 and 30 days after admission. An informed
consent was obtained from all participants and the
study was approved by the Ethical Committee of the
HEOM.
Laboratory tests
The TST was performed by trained nursing staff at
HEOM with 0.1 ml of PPD RT23 (2 tuberculin unit
[TU], Statens Serum Institute, Copenhagen, Denmark).
The reaction was read 72 h later. The cut-off point for a
positive reaction was > 5 mm induration.
Serum samples were screened for antibodies to HTLV-
1 by ELISA (Murex HTLV-1, Abbot, Dartford, UK) and
confirmed by a Western blot analysis (HTLV Blot2.4,
Genelabs, Singapore) performed in accordance with the
manufaturer’s instructions. Samples were also screened
for antibodies to HIV-1 by ELISA (Ortho-Clinical Diag-
nostics, Raritan, NJ, USA). Sputum of each patient was
examined by the Ziehl-Neelsen staining method and the
bacillary load was classified as 1+, 2+, 3+ or negative.
Culture of the sputum was also performed in
Lowenstein-Jensen culture media.
Immunological studies
Peripheral blood mononuclear cells (PBMC) were
obtained from heparinized venous blood by density gra-
dient centrifugation using Ficoll-Hypaque (Sigma Chem-
ical Co, St. Louis, MD, USA). After washing with saline,
the cells were adjusted to 3x106ml and cultured in RPMI
1640 (GIBCO Grand Island, NY, USA) plus 5% heat
inactivated human AB serum supplemented with genta-
micin and glutamine. Cells were incubated only with
medium or stimulated with PPD at concentration of
1μg/ml for 72 hours at 37°C in 5% CO2. Determination
of TNF-α, IFN-γ and IL-10 was performed by ELISA
with monoclonal anti cytokine antibodies [3]. Data
expressed in pg/ml represent the amount of protein
detected in the supernatants of cultures. The mRNA for
IL-12 was performed by real time PCR. HTLV-1 sero-
negative individuals were used as controls. RNA from
cell lysates was isolated in Tri Reagent Solution
(Ambion, Applied Biosystems, Foster City, CA, USA).
The concentration and purity of RNA as well as DNA
synthesis were assessed as previously described [31].
Briefly, for relative quantitative Real Time PCR cDNA
specific primers for IL-12 and reference gene HPRT
were purchased from RealTimePrimers.com (Real Time
primers, LLC, 7304 Mountain Ave, Elkins Park, PA
19027, USA). Relative quantitative PCR reactions were
performed on a Real-Time PCR system Step OnePLUS
AB Applied Biosystems in a 96-well microtiter plate and
a final volume of 10 μL using 0–5 μL of cDNA, 2–5 μL
of 2X SYBR Green Master mix (AB Applied Biosystems,
Foster City, CA, USA) and 30 pM specific primer mix.
The cycling conditions were as follows: 10 min polymer-
ase activation at 95°C followed by 50 cycles of 15 s at
95°C and 1 min at 60°C. All samples were amplified in
duplicate, and two negative controls per primer pair
were included in each run. Melting curve analysis was
performed immediately after amplifications. HPRT
mRNA expression was used for normalization. Relative
expression levels were obtained as mean ΔCT for each
gene using the software Step OnePLUSTM Software v2.0
(AB Applied Biosystems). Data for stimulated cultures
represent the production of cytokine obtained in culture
stimulated with PPD. In some experiments IL-12 and
anti-IL-10 were added to the cultures and IFN-γ was
measured in supernatants.
The HTLV-1 proviral load was performed after DNA
extraction from mononuclear cells as previously
described [9].
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Statistical analysis
Hospitalized pulmonary TB patients with HTLV-1 were
compared to control patients without HTLV-1 by Stu-
dent t-test for continuous variables and Pearson x2 test
for categorical variables. Fisher’s exact test was used
when one the comparison groups had an expected fre-
quency of five or less. Kaplan-Meier survival analysis
was used to compare sputum microscopy conversion
after 10 and 20 days of tuberculosis treatment. Compari-
son of TNF-α, IL-12 and IFN-γ production between the
groups was performed by the Mann Whitney U Test. All
analysis was performed with statistical software STATA
10.1 (Stata Corp, College Station, TX, USA).
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